In both articles the authors have conducted reviews of available evidence using different inclusion criteria. One article concludes that MI event risk is increased in ARB users, the other finds no difference between ARB users and control subjects.
The common ground shared by the two papers is that Angiotensin Converting Enzyme Inhibitors (ACEIs) are superior to ARBs. Furthermore, neither paper demonstrated that ARBs actually reduce MI risk; ARBs may not be "ACEIs without a cough".
Action: ACEIs remain the first line drug choice in this class of medicines. ARBs should only be used when ACEIs are not tolerated and in these cases patients should be informed of the differences in MI risk.